



2015 PROGRAM TO ACCELERATE CLINICAL TRIALS (PACT) RFP

The true test for new Alzheimer's drugs is in human clinical trials. Numerous treatments for Alzheimer's disease have been shown to be safe and to have some positive effect when tested in animal models of Alzheimer's disease. However, many of these potentially successful drugs have not been brought to human trials because of the increased cost and risk at this stage of research.

The ADDF is responding to this problem through the Program to Accelerate Clinical Trials (PACT). The goal of this Request for Proposals (RFP) is to increase the number of innovative drugs tested in humans for Alzheimer's disease, related dementias and cognitive aging. This program will fund biomarker-based pilot clinical trials for Alzheimer's disease and in some cases will also support Phase I safety testing and IND-enabling studies to accelerate new drugs into trials. The ADDF is also interested in supporting targeted pharmacological and non-pharmacological approaches to prevention and clinical biomarker development programs through this PACT RFP.

FUNDING MECHANISMS

- **Academic Program** seeks to create and support innovative translational programs in academic medical centers and universities.
- **Biotechnology Development Program** supports qualified scientific projects in existing, private, early-stage biotechnology companies. The ADDF will provide support for qualified projects in more advanced companies if a clear need for non-profit funding to support the project can be demonstrated and justified. Funding is typically made as a program-related investment.
- **Biotechnology Founders Technology Transfer Program** supports academic programs that are eligible for technology transfer and the start-up of new biotechnology companies. Up to 35% of funds from these awards may be employed for expenses related to company formation, such as administrative, legal, patent and third-party vendor costs.

Programs areas of particular interest include:

- **Repurposing** – Testing drugs approved for other indications in Alzheimer's disease clinical trials. Proposals should be hypothesis driven and drugs chosen for testing should target a mechanism of action(s) common to both diseases.
- **Therapies addressing the following targets:** Energy utilization/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury and the blood-brain barrier interface.

APPLICATION SUBMISSION GUIDELINES

The ADDF will provide funding for up to \$1,500,000 per application. Multi-year proposals will be considered. Inquiries with the ADDF staff are encouraged to determine the Foundation's interest prior to application. All applicants are required to complete an electronic "Letter of Intent" (LOI) available through our website. LOIs are due at least 2 weeks before the application deadline. After review of the LOI, ADDF may invite a full application via email with a link to the electronic application form. The ADDF will attempt to make a determination of interest within 90 days of receipt of the application. Full application guidelines and further information can be found on our website (<http://www.alzdiscovery.org>).

2015 QUARTERLY DEADLINES*

March 10

June 16

September 22

December 10

*Letter of Intent is due two weeks prior to deadline

For program-related inquiries, please contact

Diana Shineman, PhD
Director, Scientific Affairs
Phone: 212-901-8007
E-mail: dshineman@alzdiscovery.org

For application submission inquiries, please contact:

Danielle Popow
Grants Coordinator
Phone: 212-901-7998
E-mail: dpopow@alzdiscovery.org